AAD vs CAP

This forum made possible through the generous support of SDN members, donors, and sponsors. Thank you.

Over9000

Full Member
7+ Year Member
Joined
May 7, 2014
Messages
296
Reaction score
92
Old Japanese proverb (so I hear): The tallest blade of grass is the first to get cut.
 
straight from the website.... their fault for overbilling...

Dermatopathology is being scrutinized because utilization of pathology services (especially 88305) has skyrocketed. While we have concerns regarding the methodology used, a recent Government Accountability Office (GAO) report found that practices that bring dermatopathology in-house bill many more biopsies to Medicare than they did prior to internalization of pathology. The implication is that financial gain is a factor in overuse of pathology services and Congress is considering restricting office-based pathology services as a way of controlling Medicare costs. Client billing for financial gain is also placing dermatopathology at risk and threatens the ability of dermatologists to bill globally for pathology services. Further devaluation of pathology codes is likely and our very ability to practice dermatopathology may be threatened. I urge you all to read the GAO report to see firsthand what our members of Congress are reading. We cannot dismiss the legitimacy of these concerns.
 
Top